Novavax Scores Approval From Australian Regulator for COVID-19 Vaccine

Novavax Inc (NASDAQ: NVAX) said Wednesday that Australia’s national drugs regulator has granted approval for its COVID-19 vaccine.

What Happened: The Maryland-based biotechnology company said that Australia’s Therapeutic Goods Administration or TGA granted approval for provisional registration of its NVX-CoV2373 vaccine for prevention of COVID-19 in individuals 18 years of age and older.

The company said the vaccine will be supplied to Australia under the brand name Nuvaxovid.

See Also: How To Buy Novavax (NVAX) Shares

Why It Matters: Novavax and Australia …

Full story available on Benzinga.com